Intravenous Immunoglobulin as an Immunomodulating Agent in Antineutrophil Cytoplasmic Antibody–Associated Vasculitides: A French Nationwide Study of Ninety‐Two Patients

Intravenous immunoglobulin (IVIG) represents a therapeutic alternative in antineutrophil cytoplasmic antibody–associated vasculitides (AAV), but its efficacy has been evaluated in only 2 small prospective trials. The aim of this study was to evaluate the efficacy and safety of IVIG in patients with AAV.

[1]  D. Metze,et al.  Nomenclature of cutaneous vasculitides – German translation of the dermatologic addendum to the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides , 2018, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[2]  A. Fioravanti,et al.  Granulomatosis with polyangiitis and intravenous immunoglobulins: a case series and review of the literature. , 2015, Autoimmunity reviews.

[3]  A. Khasnis,et al.  Venous thromboembolism in systemic autoimmune diseases: A narrative review with emphasis on primary systemic vasculitides , 2015, Vascular medicine.

[4]  P. Ravaud,et al.  Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. , 2014, The New England journal of medicine.

[5]  O. Decaux,et al.  Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients. , 2014, Rheumatology.

[6]  P. Merkel,et al.  Efficacy of remission-induction regimens for ANCA-associated vasculitis. , 2013, The New England journal of medicine.

[7]  E. Gelfand.  Intravenous immune globulin in autoimmune and inflammatory diseases. , 2012, The New England journal of medicine.

[8]  M. Cheng,et al.  Special Considerations with the Use of Intravenous Immunoglobulin in Older Persons , 2011, Drugs & aging.

[9]  S. Kaveri,et al.  Intravenous immunoglobulin therapy in rheumatic diseases , 2011, Nature Reviews Rheumatology.

[10]  M. Ballow.  The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. , 2011, The Journal of allergy and clinical immunology.

[11]  D A Bloch,et al.  The American College of Rheumatology 1990 criteria for the classification of vasculitis. Patients and methods. , 2010, Arthritis and rheumatism.

[12]  L. Hobson‐Webb,et al.  Case-control study of thromboembolic events associated with IV immunoglobulin , 2009, Journal of Neurology.

[13]  David Steven Scott,et al.  Modification and validation of the Birmingham Vasculitis Activity Score (version 3) , 2008, Annals of the rheumatic diseases.

[14]  S. Kaveri,et al.  Modulation of the cellular immune system by intravenous immunoglobulin. , 2008, Trends in immunology.

[15]  R. Seror,et al.  High frequency of venous thromboembolic events in Churg–Strauss syndrome, Wegener’s granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients , 2008, Annals of the rheumatic diseases.

[16]  H. Gürcan,et al.  Frequency of Adverse Events Associated with Intravenous Immunoglobulin Therapy in Patients with Pemphigus or Pemphigoid , 2007, The Annals of pharmacotherapy.

[17]  D. Abramowicz,et al.  Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. , 2007, Journal of the American Society of Nephrology : JASN.

[18]  A. Achiron,et al.  Safety of intravenous immunoglobulin (IVIG) therapy. , 2007, Autoimmunity reviews.

[19]  H. Raspe,et al.  EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis , 2006, Annals of the rheumatic diseases.

[20]  L. Cavacini,et al.  Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. , 2006, The New England journal of medicine.

[21]  I. Marie,et al.  Intravenous immunoglobulin‐associated arterial and venous thrombosis; report of a series and review of the literature , 2006, The British journal of dermatology.

[22]  D. Scott,et al.  Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies , 2006, Annals of the rheumatic diseases.

[23]  D. Hamrock,et al.  Adverse events associated with intravenous immunoglobulin therapy. , 2006, International immunopharmacology.

[24]  T. Kita,et al.  Clinical Efficacy of Intravenous Immunoglobulin for Patients with MPO-ANCA-Associated Rapidly Progressive Glomerulonephritis , 2005, Nephron Clinical Practice.

[25]  G. Danieli,et al.  Long term effectiveness of intravenous immunoglobulin in Churg-Strauss syndrome , 2004, Annals of the rheumatic diseases.

[26]  F. Bonilla.  PROSPECTIVE AUDIT OF ADVERSE REACTIONS OCCURRING IN 459 PRIMARY ANTIBODY-DEFICIENT PATIENTS RECEIVING INTRAVENOUS IMMUNOGLOBULIN , 2004, Pediatrics.

[27]  H. Chapel,et al.  Prospective audit of adverse reactions occurring in 459 primary antibody‐deficient patients receiving intravenous immunoglobulin , 2003, Clinical and experimental immunology.

[28]  D. Adu,et al.  Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. , 2000, QJM : monthly journal of the Association of Physicians.

[29]  C. Gordon,et al.  Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. , 1997, Arthritis and rheumatism.

[30]  D. Jayne,et al.  Intravenous immunoglobulin as sole therapy for systemic vasculitis. , 1996, British journal of rheumatology.

[31]  W. Gross,et al.  Treatment of anti‐neutrophil cytoplasmic antibody (ANCA)‐associated systemic vasculitis with high‐dose intravenous immunoglobulin , 1995, Clinical and experimental immunology.

[32]  D. Adu,et al.  Anti‐idiotypic activity against anti‐myeloperoxidase antibodies in pooled human immunoglobulin , 1994, Clinical and experimental immunology.

[33]  D. Jayne,et al.  ANCA anti-idiotype antibodies and the treatment of systemic vasculitis with intravenous immunoglobulin. , 1993, Journal of autoimmunity.

[34]  M. Davies,et al.  Treatment of systemic vasculitis with pooled intravenous immunoglobulin , 1991, The Lancet.

[35]  M. Kazatchkine,et al.  Anti‐idiotypes against anti‐neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis , 1991, Clinical and experimental immunology.

[36]  Katsuko Sato,et al.  HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN FOR KAWASAKI DISEASE , 1983, The Lancet.

[37]  A. Hirt,et al.  HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA IN CHILDHOOD , 1981, The Lancet.

[38]  P. Merkel,et al.  2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. , 2013, Arthritis and rheumatism.

[39]  L. Mouthon,et al.  Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. , 2011, Clinical and experimental rheumatology.

[40]  R. Panush.  Rituximab versus cyclophosphamide for ANCA-associated vasculitis , 2011 .

[41]  K. Bassett,et al.  Intravenous immunoglobulin as adjuvant therapy for Wegener's granulomatosis. , 2009, The Cochrane database of systematic reviews.

[42]  L. Mouthon,et al.  Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. , 2008, Arthritis and rheumatism.

[43]  A. Gibofsky.  American College of Rheumatology. , 2002, Journal of the Medical Association of Georgia.

[44]  O. Lortholary,et al.  Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. , 1996, Medicine.

[45]  D. Jayne,et al.  Pooled intravenous immunoglobulin in the management of systemic vasculitis. , 1993, Advances in experimental medicine and biology.